After adjusting for baseline variables , no relevant differences in major adverse cardiovascular and cerebrovascular events were observed at @year ( prasugrel/clopidogrel : cardiac death @ % / @ % , myocardial infarction @ % / @ % , revascularisation @ % / @ % , stroke @ % / @ % ) .